---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Budget impact"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Budget impact. Topics: Summary: price status, Summary: comparator prices and published economic evaluations, and Summary: eligible population inputs. 3 evidence topics quoted from 32 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary/budget-impact"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Palazestrant

<a id="topic-1.1.3-1"></a>

### Summary: price status

- Palazestrant is investigational. Olema Oncology states that it has no product candidates “approved for commercial sale” and has not generated revenue from product sales, so no wholesale acquisition cost, average sales price, or FDA label exists. The company anticipates OPERA-01 top-line results in the first quarter of 2027, expects to submit the new drug application in 2027, and anticipates potential FDA approval and commercial launch in 2028.
- Commercial launch planning began in 2025, and the company anticipates a targeted field force of approximately 75 to 100 representatives. No budget impact model or cost-effectiveness analysis of palazestrant has been published.
- Company estimates of market size: “Based on our internal estimates”, the global ER+/HER2- metastatic breast cancer market represents approximately $20 billion, and the market potential for palazestrant in the U.S. and E.U. is up to $5 billion in the second- and third-line settings and up to $10 billion in the first-line setting. Alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”, the corporate presentation gives an annual U.S. incidence “estimated at ~40K” and a U.S. market potential of “~$3-5B”, labeled as an “Olema internal estimate of US market.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-1.1.3-2"></a>

### Summary: comparator prices and published economic evaluations

- Elacestrant (Orserdu): wholesale acquisition cost at commercial availability on 2/3/2023 of $21,369.00 per 30 tablets of 345 mg and $7,123.00 per 30 tablets of 86 mg; the labeled dosage is 345 mg orally once daily. A U.S. model cited a cost of $22511.06 for 30 tablets of 345 mg, with unit costs from the Centers for Medicare & Medicaid Services and AWP&AAC Medicaid.
- Imlunestrant (Inluriyo): wholesale acquisition cost of $11,250.00 per 28 tablets and $22,500.00 per 56 tablets of 200 mg (accessed 09/26/2025); the labeled dosage is 400 mg orally once daily.
- Capivasertib (Truqap): wholesale acquisition cost of $22,922.00 per 4 x 16 blister package of 160 mg or 200 mg tablets; the labeled dosage, in combination with fulvestrant, is 400 mg orally twice daily for 4 days followed by 3 days off. A U.S. model in 2025 U.S. dollars, based on wholesale acquisition cost, used a capivasertib cost of $28,332 per 4 weeks.
- Gedatolisib (Revtorpyk): $10,000 per vial, or $30,000 per 28-day cycle of treatment, as reported to the drug pricing compendia.
- Fulvestrant: a U.S. health care perspective model with a monthly cycle length used 1,129.2 per cycle (range 903.36 to 1,355.04), with drug costs calculated from 2023 average sale price data of the Centers for Medicare & Medicaid Services.
- U.S. cost-effectiveness analyses of comparators report incremental cost-effectiveness ratios of $8,672,360 per QALY gained for elacestrant compared with standard of care overall and $2,900,560 per QALY gained compared with fulvestrant in the ESR1-mutation subgroup; $128,283.61, $280,854, and $709,647 per QALY for capivasertib plus fulvestrant compared with fulvestrant alone in three models and $636,455 per QALY gained in the PIK3CA/AKT1/PTEN-altered subgroup in a fourth; and $340,153.30 per QALY gained for alpelisib plus fulvestrant. A U.S. budget impact analysis of capivasertib in the second line, in 2023 US dollars, estimated $31,939,838 in net costs over 3 years in a 1-million-member population, or $0.88 per member per month.
- NICE recommends elacestrant for ESR1-mutated disease after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor, under a commercial arrangement, with exact cost-effectiveness estimates confidential. NICE states that it is “unable to make a recommendation about the use in the NHS of imlunestrant” because the company “does not intend to make an evidence submission for the evaluation”, and gives as the reason that “the technology is unlikely to be a cost-effective use of NHS resources.” No Institute for Clinical and Economic Review assessment of therapies for this population was identified.

Source: [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf); [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Zeng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10758478/); [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [AstraZeneca Truqap blister pack availability notice (2024)](https://associationdatabase.com/aws/MSHO/asset_manager/get_file/909026); [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf); [Liang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42009253/); [Celcuity Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1603454/000119312526450161/celc-20260930.htm); [Okeke et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397977/); [Nguyen and Mital (2025)](https://pubmed.ncbi.nlm.nih.gov/39630382/); [Lang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11774713/); [Wu et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37975961/); [Nguyen and Mital (2026)](https://pubmed.ncbi.nlm.nih.gov/42305034/); [NICE TA1036 recommendation (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/1-Recommendations); [NICE TA1036 committee discussion (2025)](https://www.nice.org.uk/guidance/ta1036/chapter/3-Committee-discussion); [NICE TA1168 terminated appraisal (2026)](https://www.nice.org.uk/guidance/ta1168/chapter/advice)

<a id="topic-1.1.3-3"></a>

### Summary: eligible population inputs

- U.S. incidence and prevalence: about 321,910 new cases of invasive breast cancer will be diagnosed in women in 2026. SEER reports 6% of female breast cancer cases as distant stage at diagnosis (5-year relative survival 33.8%), an estimated 4,238,585 women living with female breast cancer in 2023, and HR+/HER2- as 70% of cases, with an age-adjusted rate of 92.9 new cases per 100,000 women based on 2019–2023 cases.
- Metastatic disease: 169 347 individuals were projected to be living with metastatic breast cancer in the United States by January 1, 2025. For 2018, the estimated number of new metastatic female breast cancer cases, de novo and recurrence, was 46 666, of which 15 800 were observed de novo cases.
- Company estimates: approximately 70% of breast cancers are ER+/HER2-, approximately 6-10% of patients present with metastatic disease at diagnosis, and a further 20-30% of patients diagnosed with early-stage disease ultimately develop metastatic disease. The corporate presentation gives an annual U.S. incidence “estimated at ~40K” alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”.
- Treatment after first-line CDK4/6 inhibitor therapy in one cohort: of 1210 participants who received a CDK4/6 inhibitor with endocrine therapy as first-line therapy from 2015 to 2020, 839 received a documented second-line therapy, which was cytotoxic chemotherapy in 249 (29.7%), endocrine monotherapy in 104 (12.4%; fulvestrant in 70, 8.3%), everolimus in 99 (11.7%), alpelisib in 16 (1.9%), and a PARP inhibitor in 4 (0.5%); 302 (36.0%) continued a CDK4/6 inhibitor.
- Real-world progression-free survival: across 18 real-world studies, the weighted average median real-world progression-free survival in the second line after a first-line CDK4/6 inhibitor was 3.9 months for single-agent endocrine therapy, 3.6 months for mTOR inhibitor with or without endocrine therapy, and 6.1 months for chemotherapy.
- ESR1 mutation and testing: OPERA-01 enrolls participants “regardless of ESR1 mutation status”, and palazestrant was dosed at 90 mg once daily in Part 2. ESR1 mutation prevalence in tissue biopsies near initiation of the first, second, and third lines was 8.1%, 27.1%, and 33.3%, and in liquid biopsies 10.4%, 37.6%, and 38.7%. In one analysis, testing rates were approximately 32% at the second line and 25% at the third line across subgroups. Medicare payment during the new Advanced Diagnostic Laboratory Test initial period is $5,000.00 for Guardant360 CDx (0242U) and $3,500.00 for FoundationOne Liquid CDx (0239U), and Medicare covers FDA-approved next-generation sequencing companion diagnostics nationally for recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer for services on or after March 16, 2018.

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf); [American Cancer Society Key Statistics for Breast Cancer (2026)](https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html); [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html); [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html); [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm); [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06); [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/); [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/); [Liao et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13710441/); [CMS ADLT list (2026)](https://cms.gov/files/document/advanced-diagnostic-laboratory-tests-under-medicare-clfs.pdf); [CMS National Coverage Determination 90.2 (2020)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=372)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
